Nisita Vittorio 4
4 · Organon & Co. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Organon (OGN) Head Nisita Vittorio Receives 125,208 RSUs
What Happened
Nisita Vittorio, Head of Global Business Services at Organon & Co. (OGN), received a grant of 125,208 restricted stock units (RSUs) on March 31, 2026. On the same date she converted previously granted derivative awards into 13,000 common shares (4,606 + 8,394). To satisfy tax withholding obligations, 4,453 shares were surrendered (1,578 and 2,875 shares) at the plan-determined price of $5.70 per share, totaling $25,383. Based on the filing math, that leaves 8,547 net shares delivered to the reporting person (13,000 converted minus 4,453 withheld). The RSU grant is recorded at $0 exercise price (typical for RSUs).
Key Details
- Transaction date: March 31, 2026. Withholding price used: $5.70 (Organon closing price on March 30, 2026).
- Converted shares: 13,000 (4,606 + 8,394) acquired via derivative exercise/conversion at $0.00.
- Shares withheld for taxes: 4,453 shares (1,578 + 2,875) surrendered at $5.70, proceeds = $8,995 and $16,388 respectively; total ~$25,383.
- New grant: 125,208 RSUs (each RSU = right to one share); vests in three equal annual installments on 3/31/2027, 3/31/2028 and 3/31/2029.
- Shares owned after transaction: not stated in the Form 4.
- Footnotes: withholding price is plan-determined closing price (F1); grant and vesting schedule details provided (F2–F5).
- Filing timeliness: Form 4 filed April 2, 2026 (filed within the standard Form 4 reporting window).
Context
These transactions reflect routine RSU vesting/conversion and tax withholding, not an open-market purchase or voluntary sale. The conversions were recorded as $0 exercise/conversion (typical for RSU settlement) and some shares were withheld to cover taxes rather than selling shares on the open market. The large new RSU grant vests over three years and does not by itself indicate a buy/sell judgment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-31+4,606→ 66,678.158 total - Tax Payment
Common Stock
[F1]2026-03-31$5.70/sh−1,578$8,995→ 65,100.158 total - Exercise/Conversion
Common Stock
2026-03-31+8,394→ 73,494.158 total - Tax Payment
Common Stock
[F1]2026-03-31$5.70/sh−2,875$16,388→ 70,619.158 total - Award
Restricted Stock Units
[F2]2026-03-31+125,208→ 125,208 total→ Common Stock (125,208 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F4]2026-03-31−4,606→ 0 total→ Common Stock (4,606 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F5]2026-03-31−8,394→ 16,790 total→ Common Stock (8,394 underlying)
Footnotes (5)
- [F1]The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSUs") were awarded.
- [F2]On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
- [F3]Each RSU represents a contingent right to receive one share of Organon common stock.
- [F4]On March 31, 2023, the Reporting Person was granted 13,818 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
- [F5]On March 31, 2025, the Reporting Person was granted 25,184 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.